Hi @harsh.beria93 , I find you as one of the investors who follows the Pharma sector and has a high allocation there. With the stunning Q2 Earnings growth of Biocon, and share price being attractive in terms of historical P/E, any comments on Biocon as a long term investment opportunity?
The Biosimilars market is expected to grow at CAGR of 25%
| Subscribe To Our Free Newsletter |
